Female Reproductive System Neoplasm

subtype

Identifier: CI-CAN-00000885
Entity page: /cancer/female-reproductive-system-neoplasm ↗
Edges: 7,253

Neighbours: 15 genes26 drugs10 trials
Drawn: 51 of 51 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Female Reproductive System Neoplasm approved for …APPROVED_FORderived15 of 21show all (up to 200)
← approved for	Gemcitabinesmall_molecule FDA (US) · approved · 2025-06-27 · in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of plati…	—	approved	Malignant Ovarian Neoplasm	1	Regulatory	openfda	graph →
approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

BRCA1 Mutation Olaparib38 active / 86 trials
Curatedlevel Asensitivity· support 5civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)no approval record in this cancercontext: Malignant Ovarian Neoplasm, Malignant Uterine Neoplasm
BRCA2 Mutation Olaparib38 active / 86 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA2 altered in 3.8% (72 / 1,882 cases, largest of 7 cohorts)no approval record in this cancercontext: Malignant Ovarian Neoplasm, Malignant Uterine Neoplasm
BRCA2 Mutation Rucaparib2 active / 22 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA2 altered in 3.8% (72 / 1,882 cases, largest of 7 cohorts)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA1 Mutation Rucaparib2 active / 22 trials
Curatedlevel Asensitivity· support 4civicObservedBRCA1 altered in 1.1% (20 / 1,882 cases, largest of 2 cohorts)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRAF V600E Vemurafenib0 active / 1 trials
Curatedlevel Bsensitivity· support 2civicObservedBRAF altered in 1.4% (26 / 1,882 cases)no approval record in this cancercontext: Malignant Ovarian Neoplasm, Ovarian Serous Adenocarcinoma
ABCB1 S893T Paclitaxel110 active / 451 trials
Curatedlevel Bsensitivity· support 1civicObservedABCB1 altered in 9.3% (23 / 248 cases, largest of 2 cohorts)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA2 Loss-of-function Olaparib38 active / 86 trials
Curatedlevel Bsensitivity· support 1civicObservedBRCA2 altered in 3.8% (72 / 1,882 cases, largest of 7 cohorts)no approval record in this cancercontext: Malignant Ovarian Neoplasm
BRCA2 Loss-of-function Talazoparib6 active / 14 trials
Curatedlevel Bsensitivity· support 1civicObservedBRCA2 altered in 3.8% (72 / 1,882 cases, largest of 7 cohorts)no approval record in this cancercontext: Malignant Ovarian Neoplasm

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Female Reproductive System Neoplasm investigated for …INVESTIGATED_FOR15 of 15
← investigated for	Paclitaxelsmall_molecule	unknown	3	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Gemcitabinesmall_molecule	unknown	3	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Dexamethasonesmall_molecule	unknown	3	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Carboplatinsmall_molecule	unknown	3	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Tremelimumabmonoclonal_antibody	unknown	2	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Pembrolizumabmonoclonal_antibody	unknown	2	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Fulvestrantsmall_molecule	unknown	2	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Durvalumabmonoclonal_antibody	unknown	2	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Abemaciclibsmall_molecule	unknown	2	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Topotecansmall_molecule	unknown	1	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Temsirolimussmall_molecule	unknown	1	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Nivolumabmonoclonal_antibody	unknown	1	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Nintedanibsmall_molecule	unknown	1	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Lucitanibsmall_molecule	unknown	1	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
← investigated for	Cisplatinsmall_molecule	unknown	1	Female Reproductive System Neoplasm	1	Curated	chembl	graph →

Female Reproductive System Neoplasm altered in cohorts of …ALTERED_INderived15 of 580show all (up to 200)
← altered in cohorts of	ADRM1 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	GATA5 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	LAMA5 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	PSMA7 45 / 57 cases (79 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	AHSG 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	ARFGEF2 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	ATP13A3 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	CABLES2 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	COL20A1 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	FNDC11 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	GP5 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	HRH3 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	KNG1 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	LSM14B 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →
← altered in cohorts of	MTG2 44 / 57 cases (77 %) · ssm · TCGA-UCS	—	—	Uterine Carcinosarcoma	1	Observed	gdc	graph →

Female Reproductive System Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 256show all (up to 200)
→ investigated in trials for	Paclitaxelsmall_molecule 451 trials (110 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	451	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall_molecule 389 trials (92 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	389	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall_molecule 267 trials (65 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	267	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 216 trials (84 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	216	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 171 trials (85 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	171	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall_molecule 108 trials (25 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	108	Observed	clinicaltrials	graph →
→ investigated in trials for	Topotecansmall_molecule 108 trials (15 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	108	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 99 trials (25 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	99	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 97 trials (26 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	97	Observed	clinicaltrials	graph →
→ investigated in trials for	Olaparibsmall molecule 86 trials (38 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	86	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 62 trials (10 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	62	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 58 trials (19 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	58	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal_antibody 51 trials (28 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	51	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 50 trials (1 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	50	Observed	clinicaltrials	graph →
→ investigated in trials for	Chemotherapy 49 trials (22 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Neoplasm	49	Observed	clinicaltrials	graph →

Female Reproductive System Neoplasm studied in …STUDIED_INderived10 of 6,381show all (up to 200)
→ studied in	NCT00043472completed Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk · condition mapped CURATED_EXACT · 6,381 trials mapped (1,872 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01247597recruiting DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study · condition mapped ONTOLOGY_EXACT · 6,381 trials mapped (1,872 active)	—	—	Ovarian Sertoli-Leydig Cell Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT01441089recruiting Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis · condition mapped CURATED_EXACT · 6,381 trials mapped (1,872 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped CURATED_EXACT · 6,381 trials mapped (1,872 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03668340Phase 2 · active not recruiting AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma · condition mapped ALIAS · 6,381 trials mapped (1,872 active)	—	—	Malignant Uterine Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03762733enrolling by invitation Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies · condition mapped CURATED_EXACT · 6,381 trials mapped (1,872 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04065009Phase 3 · active not recruiting The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer · condition mapped CURATED_BROADER · 6,381 trials mapped (1,872 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04789694Phase 3 · recruiting Prehabilitation in Gynaecological Cancer Patients · condition mapped CURATED_EXACT · 6,381 trials mapped (1,872 active)	—	—	Malignant Ovarian Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · condition mapped ONTOLOGY_EXACT · 6,381 trials mapped (1,872 active)	—	—	Endometrial Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 6,381 trials mapped (1,872 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →